

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	1	("20020018997").PN.	US-PGPUB; USPAT; EPO	OR	OFF	2005/01/18 10:02
L2	11302	immobil\$4 near5 (DNA or nucleic)	US-PGPUB; USPAT; EPO; DERWENT	OR	OFF	2005/01/18 10:03
L3	24	I2 same (bind or bound) same (compet\$3 or inhibit? or screen?)	US-PGPUB; USPAT; EPO; DERWENT	OR	OFF	2005/01/18 10:13
L4	0	I3 and (pollutant or contaminant or toxicant)	US-PGPUB; USPAT; EPO; DERWENT	OR	OFF	2005/01/18 10:13

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal641cxc

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	SEP 01	New pricing for the Save Answers for SciFinder Wizard within STN Express with Discover!
NEWS	4	OCT 28	KOREAPAT now available on STN
NEWS	5	NOV 30	PHAR reloaded with additional data
NEWS	6	DEC 01	LISA now available on STN
NEWS	7	DEC 09	12 databases to be removed from STN on December 31, 2004
NEWS	8	DEC 15	MEDLINE update schedule for December 2004
NEWS	9	DEC 17	ELCOM reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS	10	DEC 17	COMPUAB reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS	11	DEC 17	SOLIDSTATE reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS	12	DEC 17	CERAB reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS	13	DEC 17	THREE NEW FIELDS ADDED TO IFIPAT/IFIUDB/IFICDB
NEWS	14	DEC 30	EPFULL: New patent full text database to be available on STN
NEWS	15	DEC 30	CAPLUS - PATENT COVERAGE EXPANDED
NEWS	16	JAN 03	No connect-hour charges in EPFULL during January and February 2005
NEWS	17	JAN 11	CA/CAPLUS - Expanded patent coverage to include Russia (Federal Institute of Industrial Property)
NEWS EXPRESS			JANUARY 10 CURRENT WINDOWS VERSION IS V7.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 10 JANUARY 2005
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS INTER			General Internet Information
NEWS LOGIN			Welcome Banner and News Items
NEWS PHONE			Direct Dial and Telecommunication Network Access to STN
NEWS WWW			CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 10:16:19 ON 18 JAN 2005

=> file .meeting

'EVENTLINE' IS NOT A VALID FILE NAME

Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files that are available. If you have requested multiple files, you can specify a corrected file name or you can enter "IGNORE" to continue accessing the remaining file names entered.

ENTER A FILE NAME OR (IGNORE):ignore

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'AGRICOLA' ENTERED AT 10:16:26 ON 18 JAN 2005

FILE 'BIOTECHNO' ENTERED AT 10:16:26 ON 18 JAN 2005

COPYRIGHT (C) 2005 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CONFSCI' ENTERED AT 10:16:26 ON 18 JAN 2005

COPYRIGHT (C) 2005 Cambridge Scientific Abstracts (CSA)

FILE 'HEALSAFE' ENTERED AT 10:16:26 ON 18 JAN 2005

COPYRIGHT (C) 2005 Cambridge Scientific Abstracts (CSA)

FILE 'IMSDRUGCONF' ENTERED AT 10:16:26 ON 18 JAN 2005

COPYRIGHT (C) 2005 IMSWORLD Publications Ltd.

FILE 'LIFESCI' ENTERED AT 10:16:26 ON 18 JAN 2005

COPYRIGHT (C) 2005 Cambridge Scientific Abstracts (CSA)

FILE 'MEDICONF' ENTERED AT 10:16:26 ON 18 JAN 2005

COPYRIGHT (c) 2005 FAIRBASE Datenbank GmbH, Hannover, Germany

FILE 'PASCAL' ENTERED AT 10:16:26 ON 18 JAN 2005

Any reproduction or dissemination in part or in full, by means of any process and on any support whatsoever is prohibited without the prior written agreement of INIST-CNRS.

COPYRIGHT (C) 2005 INIST-CNRS. All rights reserved.

=> (nucleic or DNA) (5A) (immobilized or immobilizing) (20A) (compete or competing or inhibiting or inhibition or inhibited or competed)

L1	1 FILE AGRICOLA
L2	12 FILE BIOTECHNO
L3	0 FILE CONFSCI
L4	0 FILE HEALSAFE
L5	0 FILE IMSDRUGCONF
L6	8 FILE LIFESCI
L7	0 FILE MEDICONF
L8	3 FILE PASCAL

TOTAL FOR ALL FILES

L9	24 (NUCLEIC OR DNA) (5A) (IMMOBILIZED OR IMMOBILIZING) (20A) (COMPETE OR COMPETING OR INHIBITING OR INHIBITION OR INHIBITED OR COMPETE D)
----	---

=> dup rem

ENTER L# LIST OR (END):19

DUPLICATE IS NOT AVAILABLE IN 'IMSDRUGCONF, MEDICONF'.

ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE

PROCESSING COMPLETED FOR L9

L10	15 DUP REM L9 (9 DUPLICATES REMOVED)
-----	--------------------------------------

=> l10 and (toxicant or contaminant or pollutant)

L11	1 S L10
-----	---------

L12 0 FILE AGRICOLA
 L13 12 S L10
 L14 0 FILE BIOTECHNO
 L15 0 S L10
 L16 0 FILE CONFSCI
 L17 0 S L10
 L18 0 FILE HEALSAFE
 L19 0 S L10
 L20 0 FILE IMSDRUGCONF
 L21 2 S L10
 L22 0 FILE LIFESCI
 L23 0 S L10
 L24 0 FILE MEDICNF
 L25 0 S L10
 L26 0 FILE PASCAL

TOTAL FOR ALL FILES

L27 0 L10 AND (TOXICANT OR CONTAMINANT OR POLLUTANT)

=> d l10 ibib abs total

L10 ANSWER 1 OF 15 BIOTECHNO COPYRIGHT 2005 Elsevier Science B.V. on STM
 ACCESSION NUMBER: 2001:32142591 BIOTECHNO
 TITLE: Competitive DNA hybridization in microtitre plates for
 chicken anaemia virus
 AUTHOR: Novak R.; Ragland W.L.
 CORPORATE SOURCE: R. Novak, Division of Molecular Medicine, Institut
 Ruder Boskovic, Bijenicka 54, 10000 Zagreb, Croatia.
 E-mail: rnovak@rudjer.irb.hr
 SOURCE: Molecular and Cellular Probes, (2001), 15/1 (1-11), 21
 reference(s)
 CODEN: MCPRE6 ISSN: 0890-8508
 DOCUMENT TYPE: Journal; Article
 COUNTRY: United Kingdom
 LANGUAGE: English
 SUMMARY LANGUAGE: English

AN 2001:32142591 BIOTECHNO

AB Unlabelled chicken anaemia virus (CAV) DNA probe, produced by PCR, was
 immobilized onto nitrocellulose discs that then were fitted into
 microtitre plate wells in order to develop a competitive, non-radioactive
 hybridization test for detection of CAV. The discs were hybridized with
 either DNA extracts of buffy coats or dilutions of CAV DNA (for standard
 curves), followed by hybridization with biotin-labelled CAV DNA
 probe in excess of the immobilized, capture probe. Thus, CAV
 from sample DNA extracts and standard DNA preparations competed
 with the biotin-labelled CAV DNA probe for the
 immobilized, capture probe, decreasing subsequent colour
 development by an avidin-biotin-alkaline phosphatase detection system.
 Standard curves were log linear from 5-100 ng viral DNA with
 $r_{\text{sup.2}} \geq 0.91$. Tests were considered positive at 2 SD less than mean
 absorbence of samples from uninfected chickens, and ranged from 52 to 108
 μM viral DNA or 2 to 4.2 $\times 10^{\text{sup.1.sup.0}}$ virions $\mu\text{g.sup.-.sup.1}$
 buffy coat DNA. Blood samples from chickens infected and not infected
 with CAV at one day of age were tested for evidence of infection until 28
 days of age by viral isolation, competitive hybridization in microtitre
 plates, dot-blots, enzyme-linked immunosorbent assay (ELISA), and in situ
 hybridization on blood smears. None of the tests was positive for
 uninfected chickens. Viral isolation from buffy coats, though expensive
 and lengthy, was the most sensitive method. It detected virus in buffy
 coat from each infected chicken, while competitive hybridization detected
 72% of infected chickens, in situ hybridization 69%, dot-blots 67%, and
 ELISA 36%. Sensitivity of competitive hybridization was 0.78, and its
 specificity was 1.00. Three chickens must be sampled from an infected
 flock for a 90% chance of detecting a positive chicken at the 0.025

one-tailed level of significance, assuming 100% prevalence. .COPYRGT.
2001 Academic Press.

L10 ANSWER 2 OF 15 BIOTECHNO COPYRIGHT 2005 Elsevier Science B.V. on STN
DUPLICATE

ACCESSION NUMBER: 1999:29314815 BIOTECHNO
TITLE: Ligation of FcγRII (CD32) pivotally regulates
survival of human eosinophils
AUTHOR: Kim J.-T.; Schimming A.W.; Kita H.
CORPORATE SOURCE: Dr. H. Kita, Department of Immunology, Mayo Clinic,
Rochester, MN 55905, United States.
E-mail: kita.hirohito@mayo.edu
SOURCE: Journal of Immunology, (01 APR 1999), 162/7
(4253-4259), 44 reference(s)
CODEN: JOIMA3 ISSN: 0022-1767
DOCUMENT TYPE: Journal; Article
COUNTRY: United States
LANGUAGE: English
SUMMARY LANGUAGE: English

AN 1999:29314815 BIOTECHNO

AB The low-affinity IgG Fc receptor, FcγRII (CD32), mediates various effector functions of lymphoid and myeloid cells and is the major IgG Fc receptor expressed by human eosinophils. We investigated whether FcγRII regulates both cell survival and death of human eosinophils. When cultured in vitro without growth factors, most eosinophils undergo apoptosis within 96 h. Ligation of FcγRII by anti-CD32 mAb in solution inhibited eosinophil apoptosis and prolonged survival in the absence of growth factors. Cross-linking of human IgG bound to FcγRII by anti-human IgG Ab or of unoccupied FcγRII by aggregated human IgG also prolonged eosinophil survival. The enhanced survival with anti-CD32 mAb was inhibited by anti-granulocyte-macrophage-CSF (GM-CSF) mAb, suggesting that autocrine production of GM-CSF by eosinophils mediated survival. In fact, mRNA for GM-CSF was detected in eosinophils cultured with anti-CD32 mAb. In contrast to mAb or ligands in solution, anti-CD32 mAb or human IgG, when immobilized onto tissue culture plates, facilitated eosinophil cell death even in the presence of IL-5. Cell death induced by these **immobilized** ligands was accompanied by **DNA** fragmentation and was **inhibited** when eosinophil β.sub.2 integrin was blocked by anti-CD18 mAb, suggesting that β.sub.2 integrins play a key role in initiating eosinophil apoptosis. Thus, FcγRII may pivotally regulate both survival and death of eosinophils, depending on the manner of receptor ligation and β.sub.2 integrin involvement. Moreover, the FcγRII could provide a novel mechanism to control the number of eosinophils at inflammation sites in human diseases.

L10 ANSWER 3 OF 15 BIOTECHNO COPYRIGHT 2005 Elsevier Science B.V. on STN
DUPLICATE

ACCESSION NUMBER: 1998:28261768 BIOTECHNO
TITLE: A fibrinogen-binding protein of Staphylococcus
epidermidis
AUTHOR: Nilsson M.; Frykberg L.; Flock J.-I.; Pei L.; Lindberg
M.; Guss B.
CORPORATE SOURCE: B. Guss, Department of Microbiology, Swedish Univ. of
Agric. Sciences, Box 7025, S-750 07 Uppsala,
Sweden.
E-mail: Bengt.Guss@mikrob.slu.se
SOURCE: Infection and Immunity, (1998), 66/6 (2666-2673), 38
reference(s)
CODEN: INFIBR ISSN: 0019-9567
DOCUMENT TYPE: Journal; Article
COUNTRY: United States
LANGUAGE: English
SUMMARY LANGUAGE: English

AN 1998:28261768 BIOTECHNO

AB The present study reports on fibrinogen (Fg) binding of *Staphylococcus epidermidis*. Adhesion of different *S. epidermidis* strains to immobilized Fg was found to vary significantly between different strains, and the component responsible was found to be proteinaceous in nature. To further characterize the Fg-binding activity, a shotgun phage display library covering the *S. epidermidis* chromosome was constructed. By affinity selection (panning) against immobilized Fg, a phagemid clone, pSEFG1, was isolated, which harbors an insert with an open reading frame of .sim.1.7 kilobases. Results from binding and inhibition experiments demonstrated that the insert of pSEFG1 encodes a specific Fg-binding protein. Furthermore, affinity-purified protein encoded by pSEFG1 completely inhibited adhesion of *S. epidermidis* to immobilized Fg. By additional cloning and DNA sequence analyses, the complete gene, termed fbe, was found to consist of an open reading frame of 3,276 nucleotides encoding a protein, called Fbe, with a deduced molecular mass of .sim.119 kDa. With a second phage display library made from another clinical isolate of *S. epidermidis*, it was possible to localize the Fg-binding region to a 331- amino-acid-long fragment. PCR analysis showed that the fbe gene was found in 40 of 43 clinical isolates of *S. epidermidis*. The overall organization of Fbe resembles those of other extracellular surface proteins of staphylococci and streptococci. Sequence comparisons with earlier known proteins revealed that this protein is related to an Fg-binding protein of *Staphylococcus aureus* called clumping factor.

L10 ANSWER 4 OF 15 BIOTECHNO COPYRIGHT 2005 Elsevier Science B.V. on STN
DUPLICATE

ACCESSION NUMBER: 1997:28134636 BIOTECHNO

TITLE: Inhibitory effects of naturally occurring coumarins on the metabolic activation of benzo(a)pyrene and 7,12-dimethylbenzo(a)anthracene in cultured mouse keratinocytes

AUTHOR: Cai Y.; Baer-Dubowska W.; Ashwood-Smith M.; DiGiovanni J.

CORPORATE SOURCE: J. DiGiovanni, Univ Texas MD Anderson Cancer Center, Science Park-Research Division, Department of Carcinogenesis, PO Box 389, Smithville, TX 78957, United States.

SOURCE: Carcinogenesis, (1997), 18/1 (215-222), 51 reference(s)

(CODEN: CRNGDP ISSN: 0143-3334

DOCUMENT TYPE: Journal; Article

COUNTRY: United Kingdom

LANGUAGE: English

SUMMARY LANGUAGE: English

AN 1997:28134636 BIOTECHNO

AB Several naturally occurring coumarins to which humans are routinely exposed have been previously found to be potent inhibitors and inactivators of cytochrome P450 (P450) 1A1-mediated monooxygenase in both murine hepatic microsomes and in a reconstituted system using purified human P450 1A1. In the present study, several of these coumarins were investigated for their inhibitory effects on the metabolism and metabolic activation of benzo(a)pyrene (B(a)P) and 7,12-dimethylbenzo(a)anthracene (DMBA) in cultured mouse keratinocytes. Initial analysis of B(a)P metabolism in cultured keratinocytes showed that imperatorin, isoimperatorin, coriandrin, and bergamottin, at concentrations of 2 nM equal with B(a)P, reduced the formation of water-soluble metabolites of B(a)P by 33% to 57%. Bergamottin and coriandrin were the most potent inhibitors of the compounds examined. HPLC analysis of organic solvent-soluble metabolites of B(a)P indicated that all the coumarins tested significantly reduced the formation of individual B(a)P metabolites (including phenols, diols and tetraols). However, the greatest effect was on the formation of

B β a!P tetraols. Additional experiments determined the ability of selected coumarins to block covalent binding of B β a!P and DMBA to DNA in keratinocytes. Bergamottin preferentially inhibited the binding of B β a!P to DNA by 56%, while coriandrin preferentially inhibited the binding of DMBA to DNA by 48%. Notably, analysis of individual DNA adducts formed from B β a!P and DMBA indicated that both bergamottin and coriandrin specifically inhibited the formation of anti diol-epoxide DNA adducts derived from both hydrocarbons. The preferential inhibitory effect of bergamottin and coriandrin on the formation of anti diol-epoxide adducts derived from DMBA was further confirmed by separation of anti- and syn-diol-epoxide-DNA adducts using **immobilized** boronate chromatography. The current study demonstrates that certain naturally occurring coumarins **inhibited** metabolic activation of B β a!P and DMBA in cultured mouse keratinocytes and specifically inhibited the formation of DNA adducts derived from the anti diol-epoxide diastereomers from either hydrocarbon. The current data also suggest that certain naturally occurring coumarins may possess anticarcinogenic activity toward polycyclic aromatic hydrocarbons.

L10 ANSWER 5 OF 15 BIOTECHNO COPYRIGHT 2005 Elsevier Science B.V. on STN
DUPLICATE

ACCESSION NUMBER: 1997:27179619 BIOTECHNO
TITLE: Detection of PNA/DNA hybrid molecules by antibody Fab fragments isolated from a phage display library
AUTHOR: Hansen M.H.; Sode L.L.; Hyldig-Nielsen J.J.; Engberg J.
CORPORATE SOURCE: J. Engberg, Royal Danish School of Pharmacy, Department of Biological Sciences, Universitetsparken 2, DK-2100 Copenhagen, Denmark.
E-mail: je@charon.dfh.dk
SOURCE: Journal of Immunological Methods, (1997), 203/2 (199-207), 25 reference(s)
CODEN: JIMMBG ISSN: 0022-1759
PUBLISHER ITEM IDENT.: S0022175997000318
DOCUMENT TYPE: Journal; Article
COUNTRY: Netherlands
LANGUAGE: English
SUMMARY LANGUAGE: English

AN 1997:27179619 BIOTECHNO
AB We have isolated Fab fragments that specifically recognize duplexes formed between DNA and PNA (peptide nucleic acid) from an immunized murine phage display library. Rearranged murine Fd- and Kappa chains were assembled by PCR and cloned into a phagemid expression vector. Subsequently, affinity selection on immobilized PNA/DNA duplexes of the Fab-displaying phages resulted in the isolation of clones that uniquely recognized PNA/DNA duplexes. One of these clones was characterized in detail, and its recognition of PNA/DNA duplexes was relatively sequence independent, taking place equally well with sticky-end and blunt end PNA/DNA duplexes. Duplexes smaller than 15-mers could not be detected. The selected clone recognized neither single-stranded DNA and PNA, nor double-stranded DNA and PNA. Binding of the Fab fragments to **immobilized** PNA/DNA duplexes could be **inhibited** by PNA/DNA duplex molecules in solution, with an apparent affinity in the nanomolar range. The use of this anti PNA/DNA Fab-phage as an immunochemical reagent was demonstrated in dot blot assays.

L10 ANSWER 6 OF 15 BIOTECHNO COPYRIGHT 2005 Elsevier Science B.V. on STN
DUPLICATE

ACCESSION NUMBER: 1996:26235721 BIOTECHNO
TITLE: Role of oxidative damage and IL-1 β -converting enzyme-like proteases in Fas-based cytotoxicity exerted by effector T cells
AUTHOR: Anel A.; Gamen S.; Alava M.A.; Schmitt-Verhulst A.-M.;

Pineiro A.; Naval J.
CORPORATE SOURCE: Departamento de Bioquímica Biología, Molecular y Celular, Fac. Ciencias, Universidad de Zaragoza, 50009 Zaragoza, Spain.
SOURCE: International Immunology, (1996), 8/7 (1173-1183)
CODEN: INIMEN ISSN: 0953-8178
DOCUMENT TYPE: Journal; Article
COUNTRY: United Kingdom
LANGUAGE: English
SUMMARY LANGUAGE: English

AN 1996:26235721 BIOTECHNO

AB The implication of oxidative damage and/or intact mitochondrial function in physiological Fas-based cytotoxicity has been tested using the cytolytic hybridoma d11S and the CD8.sup.+ CTL clone KB5.C20, previously stimulated to express Fas ligand (FasL) on their surface, as effecters and U937 or U937-p.sup.0 cells (depleted of mitochondrial DNA) as targets. Immobilized anti-Fas mAb, which induced death of U937 cells, inhibited the growth of U937-p.sup.0 cells but without inducing cell death. By contrast, FasL-expressing effecters readily killed both targets, with induction of DNA fragmentation, in 20 h assays. These results demonstrate the lack of involvement of mitochondrial-derived free radicals and/or intact mitochondrial function in physiological Fas-based cytotoxicity. Supplementation of Fas-sensitive cells (Jurkat, U937, L1210Fas) with a polyunsaturated fatty acid, which induces cell death through the generation of lipid free radicals, resulted in the potentiation of Fas-based cytotoxicity. This potentiating effect, but not Fas-based cytotoxicity itself, was eliminated by the physiological antioxidant vitamin E. On the other hand, the IL-1 β -converting enzyme (ICE)-like protease tetrapeptide inhibitor Ac-YVAD-cmk partially inhibited Fas-based cytotoxicity, while the specific inhibitor of CPP32/Yama Ac-DEVD-CHO was a much more effective inhibitor of Fas-induced apoptosis. It was concluded that Fas-induced cytotoxicity was clearly dependent on ICE-like protease activation, and especially on that of CPP32 in Fas-sensitive cells, including mitochondrial DNA-depleted ones.

L10 ANSWER 7 OF 15 BIOTECHNO COPYRIGHT 2005 Elsevier Science B.V. on STN

ACCESSION NUMBER: 1994:24155200 BIOTECHNO

TITLE: Interactions between fluoroquinolones, Mg.sup.2.sup.+, DNA and DNA gyrase, studied by phase partitioning in an aqueous two-phase system and by affinity chromatography

AUTHOR: Bazile-Pham Khac S.; Moreau N.J.

CORPORATE SOURCE: Ctr. National Recherche Scientifique, CERCOA, BP 28,94320 Thiais, France.

SOURCE: Journal of Chromatography A, (1994), 668/1 (241-247)
CODEN: JCRAEY ISSN: 0021-9673

DOCUMENT TYPE: Journal; Article

COUNTRY: Netherlands

LANGUAGE: English

SUMMARY LANGUAGE: English

AN 1994:24155200 BIOTECHNO

AB The primary target of fluoroquinolones has been identified as the enzyme DNA gyrase, but the mechanism of action of these antibacterial agents is still a matter of controversy. Using partitioning in aqueous polyethylene glycol (PEG)-dextran systems, the affinities of several fluoroquinolones for DNA were determined with accuracy and at equilibrium. It was proved that the binding was strongly dependent on the ability of the drugs to bind Mg.sup.2.sup.+, with K(A) values of about 40,000 l mol.sup.-1, but was poorly related to the antibacterial activity (minimal inhibitory concentration (MIC) and gyrase inhibition). Using affinity chromatography on immobilized fluoroquinolone, it was shown that DNA gyrase was unable to bind fluoroquinolones in the absence of DNA, but that a DNA-quinolone-gyrase complex was formed in

the presence of Mg^{2+} .

L10 ANSWER 8 OF 15 BIOTECHNO COPYRIGHT 2005 Elsevier Science B.V. on STN
ACCESSION NUMBER: 1993:23180647 BIOTECHNO
TITLE: Anti-CD3-stimulated Ca^{2+} signal in individual human peripheral T cells: Activation correlates with a sustained increase in intracellular Ca^{2+}
AUTHOR: Wacholtz M.C.; Lipsky P.E.
CORPORATE SOURCE: Department of Internal Medicine, Texas University SW Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75235-8884, United States.
SOURCE: Journal of Immunology, (1993), 150/12 (5338-5349)
CODEN: JOIMA3 ISSN: 0022-1767
DOCUMENT TYPE: Journal; Article
COUNTRY: United States
LANGUAGE: English
SUMMARY LANGUAGE: English
AN 1993:23180647 BIOTECHNO
AB The changes in Ca^{2+} after mitogen stimulation of individual human peripheral T cells were examined by single cell image analysis to determine the relationship between the Ca^{2+} signal and functional outcome. Marked heterogeneity in the magnitude of increase in Ca^{2+} , in the lag time of the responses, and in the percentage of T cells that responded to mAb to CD3 and to PHA was observed. However, mitogenic stimuli that induced IL-2 production or DNA synthesis consistently generated increases in Ca^{2+} in individual T cells that were sustained for 1 to 2 h. Soluble mAb to CD3 induced an increase in Ca^{2+} that remained elevated at 60 min and led to IL-2 production and proliferation upon costimulation by phorbol ester. In contrast, cross-linking anti-CD3 with a secondary antibody foreshortened the increase in Ca^{2+} , and IL-2 production and DNA synthesis were inhibited. Immobilized anti-CD3, which can stimulate T cell proliferation and IL-2 production in the absence of phorbol ester, produced a constant sustained elevation in Ca^{2+} that lasted more than 2 h. Similarly, functional responses could be generated by concentrations of PHA that resulted in only a slow increase in Ca^{2+} that continued to rise for 1 to 2 h. Examination of the mitogen-induced sustained increases in Ca^{2+} suggested that an elevation in Ca^{2+} as small as 50 to 100 nM above control mean Ca^{2+} was associated with evidence of T cell activation. Spontaneous oscillatory changes in Ca^{2+} were observed in a small percentage of peripheral T cells although they were noted to occur frequently in Jurkat cells. Mitogenic stimulation did not consistently increase oscillations in peripheral T cells, and neither their frequency nor their magnitude correlated with IL-2 production or DNA synthesis. These observations suggest that oscillatory changes in Ca^{2+} are not a primary determinant of T cell activation. Rather, the data indicate that functional activation of T cells by PHA and anti-CD3 is correlated with the induction of a small, but sustained increase in Ca^{2+} .

L10 ANSWER 9 OF 15 LIFESCI COPYRIGHT 2005 CSA on STN
ACCESSION NUMBER: 94:50324 LIFESCI
TITLE: Inhibition of DNA immobilization to nylon membrane by soil compounds
AUTHOR: Saano, A.; Kaijalainen, S.; Lindstroem, K.
CORPORATE SOURCE: Div. Microbiol., Dep. Appl. Chem. Microbiol., Univ. Helsinki, P.O. Box 27, SF-00014 Helsinki, Finland
SOURCE: MICROB. RELEASES, (1993) vol. 2, no. 3, pp. 153-160.
ISSN: 0940-9653.

DOCUMENT TYPE: Journal
FILE SEGMENT: J; N; W2
LANGUAGE: English
SUMMARY LANGUAGE: English

AB Total DNA of pure bacterial culture was labelled with super(32)P-dCTP or dig-11-dUTP and then mixed with soil DNA extract, the product of a freeze-thaw soil DNA isolation protocol, whereafter it was immobilized on a nylon membrane. Water-soluble soil compounds present in soil DNA extract inhibited the immobilization of bacterial DNA by more than three orders of magnitude even when the soil DNA extracts were diluted 4- to 40-fold. Removal of soil compounds from the soil DNA extract by spun columns improved the sensitivity of detection by about two orders of magnitude. Agarose gel electrophoresis prior to blotting of the DNA samples containing soil DNA extract did not prevent the inhibition of immobilization of the labelled DNA by the soil compounds.

L10 ANSWER 10 OF 15 BIOTECHNO COPYRIGHT 2005 Elsevier Science B.V. on STN

ACCESSION NUMBER: 1992:22278658 BIOTECHNO

TITLE: A Na.sup.+ dependent Ca.sup.2.sup.+ exchanger generates the sustained increase in intracellular Ca.sup.2.sup.+ required for T cell activation

AUTHOR: Wacholtz M.C.; Cragoe Jr. E.J.; Lipsky P.E.

CORPORATE SOURCE: Department of Internal Medicine, University of Texas SW Medical Ctr., 5323 Harry Hines Boulevard, Dallas, TX 75235-8884, United States.

SOURCE: Journal of Immunology, (1992), 149/6 (1912-1920)

CODEN: JOIMA3 ISSN: 0022-1767

DOCUMENT TYPE: Journal; Article

COUNTRY: United States

LANGUAGE: English

SUMMARY LANGUAGE: English

AN 1992:22278658 BIOTECHNO

AB Movement of extracellular Ca.sup.2.sup.+ is required for the sustained increase in Ca^{2+} necessary for T cell activation. However, the mechanisms mediating mitogen-stimulated Ca.sup.2.sup.+ movement into T cells have not been completely delineated. To explore the possibility that a Na.sup.+ dependent Ca.sup.2.sup.+ (Na.sup.+ /Ca.sup.2.sup.+) exchanger might play a role in the mitogen-induced increases in Ca^{2+} required for T cell activation, the effects of inhibitors of this exchanger were examined. Inhibitors of Na.sup.+ /Ca.sup.2.sup.+ exchange suppressed the sustained increase in Ca^{2+} stimulated by ligation of the CD3-TCR complex, but did not affect mobilization of intracellular Ca.sup.2.sup.+ stores. Consistent with the importance of this prolonged increase in Ca^{2+} in T cell activation, Na.sup.+ /Ca.sup.2.sup.+ exchange inhibitors, but not inhibitors of the Na.sup.+ /H.sup.+ antiporter, inhibited DNA synthesis stimulated by immobilized anti-CD3 mAb. Inhibition only occurred when the agents were present during the first hours after stimulation. These agents also inhibited IL-2 production, but not expression of the IL-2R or of an early activation Ag, 4F2. Inhibition of IL-2 production did not account for the inhibition of T cell proliferation as addition of exogenous IL-2 or phorbol ester (PDB) did not overcome the inhibition. In contrast, activation pathways that are not thought to require an increase in Ca^{2+} such as IL-1 + PDB or engagement of CD28 in the presence of PDB were less sensitive to the suppressive effects of inhibitors of Na.sup.+ /Ca.sup.2.sup.+ exchange. Thus, proliferation induced by these stimuli was not suppressed by low concentrations of these inhibitors and IL-2 production induced by mAb to CD28 + PDB was not inhibited by any concentration of inhibitors of Na.sup.+ /Ca.sup.2.sup.+ exchange. These results suggest that stimulation of a Ca.sup.2.sup.+ transporter with the same spectrum of inhibition as the Na.sup.+ /Ca.sup.2.sup.+ exchanger in

other tissues mediates the sustained increase in
Ca^{sup.2.sup.} required for T cell activation after CD3
ligation.

L10 ANSWER 11 OF 15 AGRICOLA Compiled and distributed by the National
Agricultural Library of the Department of Agriculture of the United States
of America. It contains copyrighted materials. All rights reserved.
(2005) on STN

ACCESSION NUMBER: 93:2663 AGRICOLA
DOCUMENT NUMBER: IND92072253
TITLE: DNA-binding properties of an "ecdysteroid receptor"
from epithelial tissue culture cells of *Chironomus*
tentans.
AUTHOR(S): Turberg, A.; Imhof, M.; Lezzi, M.; Spindler, K.D.
CORPORATE SOURCE: Heinrich-Heine Universitat, Dusseldorf, Fed. Rep.
Germany
AVAILABILITY: DNAL (QL495.A1I57)
SOURCE: Insect biochemistry and molecular biology, June 1992.
Vol. 22, No. 4. p. 343-351
Publisher: Exeter : Pergamon Press.
CODEN: ISBCAN; ISSN: 0020-1790
NOTE: Includes references.
DOCUMENT TYPE: Article
FILE SEGMENT: Non-U.S. Imprint other than FAO
LANGUAGE: English

AB Recently an ecdysteroid binding protein ("ecdysteroid receptor") has been
identified in extracts of epithelial tissue culture cells of the dipteran
insect *Chironomus tentans*. We now show that this protein also displays
high affinity to DNA. When using a solid phase binding assay an
association rate constant of $3.3 \times 10^6 \text{ M}^{-1} \text{ s}^{-1}$ and a dissociation rate
constant of $2 \times 10^{-4} \text{ s}^{-1}$ were determined for the ecdysteroid
receptor-immobilized DNA complex at 0 degree C. An apparent equilibrium
dissociation constant of $6.1 \times 10^{-11} \text{ M}$ could be estimated from these
values indicating a high affinity binding of ecdysteroid receptors to
immobilized DNA. The binding of ecdysteroid receptors to
immobilized DNA was saturable. Only double stranded free
DNA **competed** significantly for ecdysteroid receptor binding to
immobilized DNA. Furthermore, DNA sequences
that contain ecdysone response elements (EcREs) from hormonally regulated
Drosophila genes or sequences from an ecdysteroid-inducible gene of *C.*
tentans revealed a 10-350 times higher affinity to ecdysteroid receptors
than random sequences of calf thymus DNA or from a plasmid.

L10 ANSWER 12 OF 15 BIOTECHNO COPYRIGHT 2005 Elsevier Science B.V. on STN
ACCESSION NUMBER: 1990:20314403 BIOTECHNO
TITLE: Association of glucocorticoid receptors with prostate
nuclear sites for androgen receptors and with androgen
response elements
AUTHOR: Davies P.; Rushmere N.K.
CORPORATE SOURCE: Tenovus Institute for Cancer Research, University of
Wales College of Medicine, Heath Park, Cardiff CF4
4XX, United Kingdom.
SOURCE: Journal of Molecular Endocrinology, (1990), 5/2
(117-127)
CODEN: JMLEEI ISSN: 0952-5041
DOCUMENT TYPE: Journal; Article
COUNTRY: United Kingdom
LANGUAGE: English
SUMMARY LANGUAGE: English

AN 1990:20314403 BIOTECHNO

AB Ventral prostate glands of intact normal rats contained low levels (2500
molecules/cell) of high-affinity (dissociation constant K_d 0.57 nmol/l)
glucocorticoid receptor (GR). Levels of GR increased 2.8-fold 1 day after
castration, and 4.3-fold 3 days after castration. Nuclear GR increased

from a normal value of 1150 molecules/nucleus to 5200 molecules/nucleus 3 days after castration. The greater increase in intranuclear GR was in that associated with oligomeric chromatin. Although nuclear GR never approached the normal population of nuclear androgen receptors (AR; approximately 16000 molecules/nucleus), the selective rise in chromatin-associated receptors ensured that almost 60% of chromatin sites remained occupied. GR associated with prostate nuclear structures in a similar manner to AR, and exogenous GR bound saturably and with high affinity ($K(d)$ 100 pmol/l) to a similar number of sites as did AR. Both steroid receptors apparently competed for the same sites. In DNA-cellulose competition analyses, synthetic oligonucleotides containing glucocorticoid response elements or putative androgen response elements **competed** similarly against **immobilized** non-specific DNA for both AR and GR. In view of these data and information from other sources, it is probable that the role of GR in the prostate should be assessed with a view to understanding its action under conditions of androgen deprivation.

L10 ANSWER 13 OF 15 BIOTECHNO COPYRIGHT 2005 Elsevier Science B.V. on STN

ACCESSION NUMBER: 1985:16242804 BIOTECHNO
 TITLE: Interaction of DNA with connective tissue matrix proteins reveals preferential binding to type V collagen
 AUTHOR: Gay S.; Losman M.J.; Koopman W.J.; Miller E.J.
 CORPORATE SOURCE: Division of Clinical Immunology and Rheumatology, Department of Medicine and The Institute of Dental Research, University of Alabama at Birmingham, Birmingham, AL 35294, United States.
 SOURCE: Journal of Immunology, (1985), 135/2 (1097-1100)
 CODEN: JOIMA3
 DOCUMENT TYPE: Journal; Article
 COUNTRY: United States
 LANGUAGE: English
 AN 1985:16242804 BIOTECHNO
 AB The interaction of DNA with type I to VI collagens and laminin was studied in vitro in systems in which the connective tissue components were immobilized, as well as when in solution. In studies on **immobilized** components, significant binding of DNA was observed only for type V collagen, and the binding of radiolabeled DNA to this component could be effectively **inhibited** in a concentration-dependent manner by the addition of unlabeled DNA. Similar results were observed in solution assays in which it was observed that DNA binding to type V collagen was dependent on the native triple-helical conformation of the collagen. The preferential binding of DNA to native type V collagen may be due to the relative basicity of type V collagen chains, as well as the unique spatial arrangement of amino acid side chains in the native molecules. The data are of potential clinical relevance in that binding of DNA to type V collagen may represent at least one component of the mechanism whereby DNA and its immune complexes are deposited in connective tissues in certain pathologic conditions.

L10 ANSWER 14 OF 15 LIFESCI COPYRIGHT 2005 CSA on STN

ACCESSION NUMBER: 84:12482 LIFESCI
 TITLE: Interaction of the 1 alpha ,25-dihydroxyvitamin D sub(3) receptor with RNA and synthetic polyribonucleotides.
 AUTHOR: Franceschi, R.T.
 CORPORATE SOURCE: Dep. Nutr., Harvard Sch. Public Health, Boston, MA 02115, USA
 SOURCE: PROC. NATL. ACAD. SCI. USA., (1984) vol. 81, no. 8, pp. 2337-2341.
 DOCUMENT TYPE: Journal
 FILE SEGMENT: L; N
 LANGUAGE: English
 SUMMARY LANGUAGE: English

AB The interaction of the 1 alpha ,25-dihydroxyvitamin D sub(3) receptor with RNA and synthetic polynucleotides has been examined by using receptor from rachitic chicken intestine. Total intestinal RNA inhibited the binding of receptor to calf thymus DNA-cellulose with an efficiency equivalent to single-stranded DNA. Receptor also bound to immobilized intestinal RNA and polynucleotides. The KCl concentration necessary to disrupt binding to a given polynucleotide generally paralleled the activity of that molecule in DNA-cellulose inhibition and displacement assays. The results suggest that the 1 alpha ,25-dihydroxyvitamin D sub(3) receptor can interact with RNA as well as DNA.

L10 ANSWER 15 OF 15 BIOTECHNO COPYRIGHT 2005 Elsevier Science B.V. on STN DUPLICATE

ACCESSION NUMBER: 1983:13107061 BIOTECHNO
TITLE: Simian virus 40 large tumor antigen on replicating viral chromatin: Tight binding and localization on the viral genome
AUTHOR: Stahl H.; Knippers R.
CORPORATE SOURCE: Fak. Biol., Univ. Konstanz, D-7750 Konstanz, Germany.
SOURCE: Journal of Virology, (1983), 47/1 (65-76)
CODEN: JOVIAM
DOCUMENT TYPE: Journal; Article
COUNTRY: United States
LANGUAGE: English

AN 1983:13107061 BIOTECHNO

AB Pulse-labeled simian virus 40 (SV40) chromatin as well as uniformly labeled viral chromatin are immunoprecipitable by an SV40-specific tumor antiserum and therefore contain bound tumor antigen (T antigen). Single-stranded calf thymus DNA, immobilized on cellulose, competes effectively for T antigen binding with uniformly labeled nonreplicating, but not with pulse-labeled replicating, chromatin. Furthermore, T antigen dissociates in 0.5 M NaCl from nonreplicating chromatin and from purified SV40 DNA, whereas most T antigen remains associated with replicating chromatin even in the presence of 1.2 to 1.5 M NaCl. We used filtration through DNA-cellulose columns and treatment with high salt to prepare pulse-labeled immunoreactive viral chromatin. The viral DNA was digested before, and in other experiments after, immunoprecipitation with the restriction endonuclease HindIII. We found that SV40 DNA sequences, most probably representing the entire genome, remain in the immunoprecipitate after HindIII digestion, indicating an association of T antigen with origin-distal sections of replicating viral DNA. The results suggest that T antigen in replicating chromatin may be bound to regions close to replicating points. We performed control experiments with in vitro-formed complexes of T antigen and SV40 DNA. When these complexes were immunoprecipitated and HindIII digested we found, in agreement with previous studies, that only the origin containing the HindIII C fragment carried bound T antigen.

=> file .chemistry
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
37.67	37.88

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 10:22:06 ON 18 JAN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOTECHNO' ENTERED AT 10:22:06 ON 18 JAN 2005
COPYRIGHT (C) 2005 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'COMPENDEX' ENTERED AT 10:22:06 ON 18 JAN 2005
Compendex Compilation and Indexing (C) 2005
Elsevier Engineering Information Inc (EEI). All rights reserved.
Compendex (R) is a registered Trademark of Elsevier Engineering Information Inc.

FILE 'ANABSTR' ENTERED AT 10:22:06 ON 18 JAN 2005
COPYRIGHT (c) 2005 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'CERAB' ENTERED AT 10:22:06 ON 18 JAN 2005
COPYRIGHT (C) 2005 Cambridge Scientific Abstracts (CSA)

FILE 'METADEX' ENTERED AT 10:22:06 ON 18 JAN 2005
COPYRIGHT (c) 2005 Cambridge Scientific Abstracts (CSA)

FILE 'USPATFULL' ENTERED AT 10:22:06 ON 18 JAN 2005
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

=> (nucleic or DNA) (5A) (immobilized or immobilizing) (20A) (compete or competing or
inhibiting or inhibition or inhibited or competed)

L28	17	FILE CAPLUS
L29	12	FILE BIOTECHNO
L30	0	FILE COMPENDEX
L31	1	FILE ANABSTR
L32	0	FILE CERAB
L33	0	FILE METADEX
L34	39	FILE USPATFULL

TOTAL FOR ALL FILES

L35	69	(NUCLEIC OR DNA) (5A) (IMMOBILIZED OR IMMOBILIZING) (20A) (COMPETE OR COMPETING OR INHIBITING OR INHIBITION OR INHIBITED OR COMPETE D)
-----	----	--

=> l35 and (toxicant or pollutant or contaminant)

L36	0	FILE CAPLUS
L37	0	FILE BIOTECHNO
L38	0	FILE COMPENDEX
L39	0	FILE ANABSTR
L40	0	FILE CERAB
L41	0	FILE METADEX
L42	13	FILE USPATFULL

TOTAL FOR ALL FILES

L43	13	L35 AND (TOXICANT OR POLLUTANT OR CONTAMINANT)
-----	----	--

=> l43 and screen

L44	0	FILE CAPLUS
L45	0	FILE BIOTECHNO
L46	0	FILE COMPENDEX
L47	0	FILE ANABSTR
L48	0	FILE CERAB
L49	0	FILE METADEX
L50	9	FILE USPATFULL

TOTAL FOR ALL FILES

L51	9	L43 AND SCREEN
-----	---	----------------

=> d l51 ibib abs total

L51 ANSWER 1 OF 9 USPATFULL on STN

ACCESSION NUMBER: 2004:320925 USPATFULL

TITLE: Dynamic action reference tools

INVENTOR(S): Roberts, Radclyffe L., Seattle, WA, UNITED STATES
De Figuereido, Paul, Kenmore, WA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004253578	A1	20041216	
APPLICATION INFO.:	US 2004-474298	A1	20040720	(10)
	WO 2002-US10566		20020402	

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-281133P	20010402 (60)
	US 2001-281342P	20010403 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	JONES DAY, 222 EAST 41ST ST, NEW YORK, NY, 10017	
NUMBER OF CLAIMS:	41	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	6 Drawing Page(s)	
LINE COUNT:	7518	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides Dynamic Action Reference Tools, or DARTs, and methods of making and using DARTs. DARTs can be used, for example, for the isolation and analysis of nucleic acids, polypeptides, and the like, for regulating biological activities and investigating inter-molecular interactions, and the like. A DART is a molecule that includes a Molecular Shaft covalently linked to a Linkage Polypeptide that is covalently linked to a Molecular Point. DARTs, and DART libraries, can be formed and manipulated in vivo or in vitro. DARTs can be purified, and portions of DARTs can be exchanged with portions of other DARTs.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L51 ANSWER 2 OF 9 USPATFULL on STN

ACCESSION NUMBER: 2003:306411 USPATFULL
 TITLE: Selective extraction of DNA from groups of cells
 INVENTOR(S): Bille, Todd William, Lorton, VA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003215845	A1	20031120	
APPLICATION INFO.:	US 2003-370143	A1	20030219	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-358464P	20020219 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Sherry M. Knowles, King & Spalding, 45th Floor, 191 Peachtree Street, N.E., Atlanta, GA, 30303	
NUMBER OF CLAIMS:	50	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	5 Drawing Page(s)	
LINE COUNT:	2226	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention is in the area of selective extraction of DNA from groups of cells. Selective lysis of a particular cell type within a cellular mixture is performed and then the mixture is separated with a filter that allows the DNA from the lysed cells to flow through the filter, while not allowing the unlysed cells to pass through, thereby selectively extracting the DNA from a particular cell type. In one specific embodiment, spermatozoa DNA can be isolated from biological samples which also contain epithelial cells. Methods and kits are also provided which allow for the sequential extraction of DNA from mixtures of cells. The DNA in the sample can be from human, animal or vegetal origin, or any combination of human, animal or vegetal DNA.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L51 ANSWER 3 OF 9 USPATFULL on STN

ACCESSION NUMBER: 2003:258639 USPATFULL

TITLE: 207 human secreted proteins

INVENTOR(S): Ni, Jian, Germantown, MD, UNITED STATES
Ebner, Reinhard, Gaithersburg, MD, UNITED STATES
LaFleur, David W., Washington, DC, UNITED STATES
Moore, Paul A., Germantown, MD, UNITED STATES
Olsen, Henrik S., Gaithersburg, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Soppet, Daniel R., Centreville, VA, UNITED STATES
Young, Paul E., Gaithersburg, MD, UNITED STATES
Shi, Yanggu, Gaithersburg, MD, UNITED STATES
Florence, Kimberly A., Rockville, MD, UNITED STATES
Wei, Ying-Fei, Berkeley, CA, UNITED STATES
Florence, Charles, Rockville, MD, UNITED STATES
Hu, Jing-Shan, Mountain View, CA, UNITED STATES
Li, Yi, Sunnyvale, CA, UNITED STATES
Kyaw, Hla, Frederick, MD, UNITED STATES
Fischer, Carrie L., Burke, VA, UNITED STATES
Ferrie, Ann M., Painted Post, NY, UNITED STATES
Fan, Ping, Potomac, MD, UNITED STATES
Feng, Ping, Gaithersburg, MD, UNITED STATES
Endress, Gregory A., Florence, MA, UNITED STATES
Dillon, Patrick J., Carlsbad, CA, UNITED STATES
Carter, Kenneth C., North Potomac, MD, UNITED STATES
Brewer, Laurie A., St. Paul, MN, UNITED STATES
Yu, Guo-Liang, Berkeley, CA, UNITED STATES
Zeng, Zhizhen, Lansdale, PA, UNITED STATES
Greene, John M., Gaithersburg, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003181692	A1	20030925
APPLICATION INFO.:	US 2001-933767	A1	20010822 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2001-US5614, filed on 21 Feb 2001, PENDING Continuation-in-part of Ser. No. US 1998-205258, filed on 4 Dec 1998, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-184836P	20000224 (60)
	US 2000-193170P	20000329 (60)
	US 1997-48885P	19970606 (60)
	US 1997-49375P	19970606 (60)
	US 1997-48881P	19970606 (60)
	US 1997-48880P	19970606 (60)
	US 1997-48896P	19970606 (60)
	US 1997-49020P	19970606 (60)
	US 1997-48876P	19970606 (60)
	US 1997-48895P	19970606 (60)
	US 1997-48884P	19970606 (60)
	US 1997-48894P	19970606 (60)
	US 1997-48971P	19970606 (60)
	US 1997-48964P	19970606 (60)
	US 1997-48882P	19970606 (60)
	US 1997-48899P	19970606 (60)
	US 1997-48893P	19970606 (60)
	US 1997-48900P	19970606 (60)
	US 1997-48901P	19970606 (60)
	US 1997-48892P	19970606 (60)

US 1997-48915P	19970606 (60)
US 1997-49019P	19970606 (60)
US 1997-48970P	19970606 (60)
US 1997-48972P	19970606 (60)
US 1997-48916P	19970606 (60)
US 1997-49373P	19970606 (60)
US 1997-48875P	19970606 (60)
US 1997-49374P	19970606 (60)
US 1997-48917P	19970606 (60)
US 1997-48949P	19970606 (60)
US 1997-48974P	19970606 (60)
US 1997-48883P	19970606 (60)
US 1997-48897P	19970606 (60)
US 1997-48898P	19970606 (60)
US 1997-48962P	19970606 (60)
US 1997-48963P	19970606 (60)
US 1997-48877P	19970606 (60)
US 1997-48878P	19970606 (60)
US 1997-57645P	19970905 (60)
US 1997-57642P	19970905 (60)
US 1997-57668P	19970905 (60)
US 1997-57635P	19970905 (60)
US 1997-57627P	19970905 (60)
US 1997-57667P	19970905 (60)
US 1997-57666P	19970905 (60)
US 1997-57764P	19970905 (60)
US 1997-57643P	19970905 (60)
US 1997-57769P	19970905 (60)
US 1997-57763P	19970905 (60)
US 1997-57650P	19970905 (60)
US 1997-57584P	19970905 (60)
US 1997-57647P	19970905 (60)
US 1997-57661P	19970905 (60)
US 1997-57662P	19970905 (60)
US 1997-57646P	19970905 (60)
US 1997-57654P	19970905 (60)
US 1997-57651P	19970905 (60)
US 1997-57644P	19970905 (60)
US 1997-57765P	19970905 (60)
US 1997-57762P	19970905 (60)
US 1997-57775P	19970905 (60)
US 1997-57648P	19970905 (60)
US 1997-57774P	19970905 (60)
US 1997-57649P	19970905 (60)
US 1997-57770P	19970905 (60)
US 1997-57771P	19970905 (60)
US 1997-57761P	19970905 (60)
US 1997-57760P	19970905 (60)
US 1997-57776P	19970905 (60)
US 1997-57778P	19970905 (60)
US 1997-57629P	19970905 (60)
US 1997-57628P	19970905 (60)
US 1997-57777P	19970905 (60)
US 1997-57634P	19970905 (60)
US 1997-70923P	19971218 (60)
US 1998-92921P	19980715 (60)
US 1998-94657P	19980730 (60)
US 1997-70923P	19971218 (60)
US 1998-92921P	19980715 (60)
US 1998-94657P	19980730 (60)

DOCUMENT TYPE:

Utility

FILE SEGMENT:

APPLICATION

LEGAL REPRESENTATIVE:

HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Page(s)
LINE COUNT: 32746

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L51 ANSWER 4 OF 9 USPATFULL on STN

ACCESSION NUMBER: 2003:237907 USPATFULL
TITLE: Compositions and methods for the therapy and diagnosis of colon cancer
INVENTOR(S): King, Gordon E., Shoreline, WA, UNITED STATES
Meagher, Madeleine Joy, Seattle, WA, UNITED STATES
Xu, Jiangchun, Bellevue, WA, UNITED STATES
Secrist, Heather, Seattle, WA, UNITED STATES
Jiang, Yuqiu, Kent, WA, UNITED STATES
PATENT ASSIGNEE(S): Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003166064	A1	20030904
APPLICATION INFO.:	US 2002-99926	A1	20020314 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-33528, filed on 26 Dec 2001, PENDING Continuation-in-part of Ser. No. US 2001-920300, filed on 31 Jul 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-302051P	20010629 (60)
	US 2001-279763P	20010328 (60)
	US 2000-223283P	20000803 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092	
NUMBER OF CLAIMS:	17	
EXEMPLARY CLAIM:	1	
LINE COUNT:	8531	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, particularly colon cancer, are disclosed. Illustrative compositions comprise one or more colon tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly colon cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L51 ANSWER 5 OF 9 USPATFULL on STN

ACCESSION NUMBER: 2003:106233 USPATFULL
TITLE: Compositions and methods for the therapy and diagnosis of pancreatic cancer
INVENTOR(S): Benson, Darin R., Seattle, WA, UNITED STATES

Kalos, Michael D., Seattle, WA, UNITED STATES
 Lodes, Michael J., Seattle, WA, UNITED STATES
 Persing, David H., Redmond, WA, UNITED STATES
 Hepler, William T., Seattle, WA, UNITED STATES
 Jiang, Yuqiu, Kent, WA, UNITED STATES
 Corixa Corporation, Seattle, WA, UNITED STATES, 98104
 (U.S. corporation)

PATENT ASSIGNEE(S) :

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003073144	A1	20030417
APPLICATION INFO.:	US 2002-60036	A1	20020130 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-333626P	20011127 (60)
	US 2001-305484P	20010712 (60)
	US 2001-265305P	20010130 (60)
	US 2001-267568P	20010209 (60)
	US 2001-313999P	20010820 (60)
	US 2001-291631P	20010516 (60)
	US 2001-287112P	20010428 (60)
	US 2001-278651P	20010321 (60)
	US 2001-265682P	20010131 (60)

DOCUMENT TYPE: Utility
 FILE SEGMENT: APPLICATION
 LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092

NUMBER OF CLAIMS: 17
 EXEMPLARY CLAIM: 1
 LINE COUNT: 14253

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, particularly pancreatic cancer, are disclosed. Illustrative compositions comprise one or more pancreatic tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly pancreatic cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L51 ANSWER 6 OF 9 USPATFULL on STN

ACCESSION NUMBER: 2002:272801 USPATFULL
 TITLE: Compositions and methods for the therapy and diagnosis of colon cancer
 INVENTOR(S): Stolk, John A., Bothell, WA, UNITED STATES
 Xu, Jiangchun, Bellevue, WA, UNITED STATES
 Chenault, Ruth A., Seattle, WA, UNITED STATES
 Meagher, Madeleine Joy, Seattle, WA, UNITED STATES
 PATENT ASSIGNEE(S): Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002150922	A1	20021017
APPLICATION INFO.:	US 2001-998598	A1	20011116 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-304037P	20010710 (60)
	US 2001-279670P	20010328 (60)
	US 2001-267011P	20010206 (60)

US 2000-252222P 20001120 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH
AVE, SUITE 6300, SEATTLE, WA, 98104-7092
NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1
LINE COUNT: 9233

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, particularly colon cancer, are disclosed. Illustrative compositions comprise one or more colon tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly colon cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L51 ANSWER 7 OF 9 USPATFULL on STN

ACCESSION NUMBER: 2002:265949 USPATFULL
TITLE: Surface transfection and expression procedure
INVENTOR(S): Uhler, Michael D., Ann Arbor, MI, UNITED STATES
PATENT ASSIGNEE(S): Regents of the University of Michigan, Ann Arbor, MI,
UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002146825	A1	20021010
APPLICATION INFO.:	US 2001-960454	A1	20010921 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-245892P	20001103 (60)
	US 2001-305552P	20010713 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MEDLEN & CARROLL, LLP, 101 HOWARD STREET, SUITE 350, SAN FRANCISCO, CA, 94105	
NUMBER OF CLAIMS:	37	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	3 Drawing Page(s)	
LINE COUNT:	4075	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a method of transfecting cells comprising applying cells directly onto nucleic acids which are immobilized in transfection complexes on a surface and which transfect the cells. Preferably, the nucleic acids are immobilized in an array. In another aspect of the present invention, the method further includes expression of the nucleic acids in the transfected cells. In yet another aspect of the present invention, the method further comprises detecting the expression of the nucleic acids in the transfected cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L51 ANSWER 8 OF 9 USPATFULL on STN

ACCESSION NUMBER: 2002:243051 USPATFULL
TITLE: Compositions and methods for the therapy and diagnosis of ovarian cancer
INVENTOR(S): Algate, Paul A., Issaquah, WA, UNITED STATES
Jones, Robert, Seattle, WA, UNITED STATES
Harlocker, Susan L., Seattle, WA, UNITED STATES
PATENT ASSIGNEE(S): Corixa Corporation, Seattle, WA, UNITED STATES, 98104

(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002132237	A1	20020919
APPLICATION INFO.:	US 2001-867701	A1	20010529 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-207484P	20000526 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092	
NUMBER OF CLAIMS:	11	
EXEMPLARY CLAIM:	1	
LINE COUNT:	25718	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, particularly ovarian cancer, are disclosed. Illustrative compositions comprise one or more ovarian tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly ovarian cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L51 ANSWER 9 OF 9 USPATFULL on STN

ACCESSION NUMBER: 2000:105377 USPATFULL
TITLE: Immobilizing and processing specimens on matrix materials for the identification of nucleic acid sequences
INVENTOR(S): Stapleton, Marilyn J., Durham, NC, United States
Sundseth, Rebecca, Durham, NC, United States
Wei, Ke, Durham, NC, United States
PATENT ASSIGNEE(S): GeneTec Corporation, Durham, NC, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6103192		20000815
APPLICATION INFO.:	US 1998-60282		19980414 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-43683P	19970414 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Stucker, Jeffrey	
NUMBER OF CLAIMS:	16	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 1 Drawing Page(s)	
LINE COUNT:	1514	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention is a method and device for collecting and processing a biological specimen for the analyses of nucleic acids. A device comprises a matrix to which cells and viruses adhere and a handle to manipulate the matrix. The devices are used to collect, dry, transport, store and process small amounts of blood or other tissue. The matrix of the device is transferred to a reaction tube and amplifying reagents added to it. Nucleic acid sequences and relative quantities are detected and analyzed from the same specimen. The relative amounts of amplified

nucleic acid from one or more particular RNA sequences are compared to one another and to the amount of amplified nucleic acid from DNA sequences serving as an internal control for the number of biological units per specimen. The relative amounts of amplified viral sequences from suspected viruses in the biological specimen and from recombinant viral particles serving as a viral quantitation standard enable estimation of viral burden in a given quantity of specimen.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.